Dogwood Therapeutics, Inc. (DWTX) has a negative trailing P/E of -0.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -116.21%, forward earnings yield 65.36%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -38.2 | 0.00 | -64.07 | 0.00 | - |
| 2019 | -32.6 | -1.91 | -16.34 | 0.00 | - |
| 2020 | -3.6 | -0.01 | 1.24 | 0.00 | 0.20% |
| 2021 | -2.7 | 0.30 | 2.94 | 0.00 | - |
| 2022 | -0.2 | 0.01 | 0.36 | 0.00 | - |
| 2023 | -2.0 | 0.03 | 2.84 | 0.00 | - |
| 2024 | -0.2 | 0.00 | 0.04 | 0.00 | - |
| 2025 | -1.0 | 0.02 | 0.46 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-10.93 | $0.00 | $-2.11M | - |
| 2019 | $-12.80 | $0.00 | $-2.47M | - |
| 2020 | $-52.50 | $0.00 | $-10.35M | - |
| 2021 | $-47.90 | $0.00 | $-15.96M | - |
| 2022 | $-27.66 | $0.00 | $-12.25M | - |
| 2023 | $-7.05 | $0.00 | $-5.3M | - |
| 2024 | $-9.42 | $0.00 | $-12.35M | - |
| 2025 | $-4.32 | $0.00 | $-34.26M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.02 | $-1.46 – $-0.58 | $128.77M | $128.77M – $128.77M | 2 |
| 2027 | $-1.23 | $-1.89 – $-0.55 | $18.73M | $18.73M – $18.73M | 2 |
| 2028 | $-1.30 | $-2.22 – $-0.52 | $9.42M | $9.42M – $9.42M | 3 |
| 2029 | $-0.09 | $-0.09 – $-0.09 | $57.4M | $57.4M – $57.4M | 1 |
| 2030 | $1.12 | $1.12 – $1.12 | $69.67M | $69.67M – $69.67M | 1 |
